STAT News Reporter Adam Feuerstein Responds To Tweet On Lancet Report On Remdesivir Trial, Says 'This Is The Negative China Study...We Reported On Last Week;' Lancet Study Suggests Drug Not Associated With Significant Clinical Benefits
Benzinga Newsdesk